The HD Semaglutide 10 Pen is a multi-dose research peptide format of the GLP-1 receptor agonist semaglutide, supplied in South Africa for in vitro and non-clinical laboratory use. As of SAHPRA's 8 November 2024 position statement, semaglutide remains a scheduled medicinal active ingredient under the Medicines and Related Substances Act 101 of 1965, and only Ozempic is a registered semaglutide product locally. Any pen-format supply intended for research must be handled under appropriate institutional controls, with documentation reflecting non-clinical use. Procurement teams looking to buy semaglutide research peptide South Africa-side should confirm that their intended protocol sits within an authorised in vitro or non-clinical framework before ordering.
This page covers HD Labs-specific formulation notes (concentration, pen mechanism, dose-per-click) alongside the peer-reviewed metabolic pharmacology that justifies semaglutide's selection as a GLP-1 agonist research tool. Ordering information and scientific rationale sit side by side.
Key Takeaways
- The HD Labs 10 Pen delivers 10 fixed-dose actuations of semaglutide for in vitro and non-clinical research only; it is not a registered medicine in South Africa.
- Exact concentration (mg/mL) and volume per actuation (µL) are not published by HD Labs; request the batch certificate of analysis directly from the supplier before procurement.
- Semaglutide's long plasma half-life (165–184 hours) and GLP-1R mechanism make it a reference compound for isolating GLP-1-mediated effects in multi-agonist research stacks.
- Choose the 10-dose format for extended dose-ranging studies; choose the Body Pharm 6 Pen for shorter pilots to reduce wastage.
- All protocols must sit within an authorised in vitro or non-clinical framework with institutional ethics sign-off before ordering.
What Is the HD Labs Semaglutide 10 Pen?
The HD Labs Semaglutide 10 Pen is a multi-dose research peptide presentation of semaglutide, a long-acting GLP-1 receptor agonist (molecular weight 4,113.58 Da). It is supplied in a pre-filled pen that delivers up to 10 fixed-dose actuations for in vitro and non-clinical laboratory work only. It is not a registered medicine in South Africa and carries no therapeutic indication.
Semaglutide is a GLP-1 analogue with a plasma half-life of roughly 165–184 hours in humans, which supports the once-weekly dosing schedule used in the clinical Ozempic product. The HD Labs pen mirrors that delivery geometry: fixed-volume click, sealed cartridge. It is sold strictly as a research-grade reagent, not a finished pharmaceutical. SAHPRA's November 2024 position statement is explicit that semaglutide remains a scheduled active ingredient regardless of how a supplier labels the format. The pen must be logged, stored, and consumed under institutional research controls.
Researchers comparing pen capacities typically benchmark this 10-actuation unit against the Body Pharm Semaglutide 6 Pen, or evaluate it alongside dual-agonist tools such as Tirsema when designing combination GLP-1 protocols.
Exact mg/mL concentration and µL-per-click figures are not published in any HD Labs document we could locate. Request these directly from the supplier before procurement.
HD Labs 10 Pen: Full Product Specifications
The table below reflects what we could independently verify against HD Labs documentation and SAHPRA's regulatory framework as of May 2026. Several fields remain because HD Labs has not published a publicly accessible certificate of analysis or technical insert for the 10 Pen format. Procurement officers should request the dated CoA directly from the supplier and reconcile the figures before raising a purchase order.
| Specification | Value | Verification status (May 2026) |
|---|---|---|
| Peptide identity | Semaglutide (GLP-1 analogue, MW 4,113.58 Da) | Verified |
| Manufacturer | HD Labs | Verified (vendor declaration) |
| Format | Multi-dose pre-filled pen | Verified (vendor declaration) |
| Number of fixed-dose actuations | 10 | Verified (product name) |
| Total peptide content (mg) | Not published | |
| Concentration (mg/mL) | Not published | |
| Volume per actuation (µL) | Not published | |
| Purity grade | Typically advertised ≥98% by HPLC across the category | for HD Labs specifically |
| Batch testing method | HPLC ± MS (industry norm) | for HD Labs specifically |
| Recommended storage | 2–8 °C, protected from light, avoid freeze-thaw | Inferred from semaglutide stability profile; HD Labs post-opening duration |
| Recommended reconstitution solvent | Not applicable, pen ships pre-filled; bacteriostatic water or sterile saline only if a researcher elects to aspirate and dilute | Methodology note |
| Regulatory status (ZA) | Scheduled active ingredient under the Medicines and Related Substances Act; not registered with SAHPRA | Verified |
| Last spec verification | 12 May 2026 | , |
Researchers cross-referencing pen geometry should compare these fields against the Body Pharm Semaglutide 6 Pen sheet, or against the dual-agonist Tirsema profile when designing combination GLP-1 protocols.
Semaglutide as a GLP-1 Agonist: Research Background
Semaglutide is a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist with a molecular weight of 4,113.58 Da, engineered for prolonged plasma half-life via a C-18 fatty diacid side chain that promotes albumin binding.
In research models, the molecule binds GLP-1R on pancreatic beta cells, triggering Gαs-coupled adenylate cyclase activation. This raises intracellular cAMP and potentiates glucose-stimulated insulin secretion whilst suppressing glucagon release from alpha cells. Parallel actions on hypothalamic arcuate and paraventricular nuclei reduce food intake by modulating satiety signalling. Delayed gastric emptying flattens post-prandial glucose excursions.
Preclinical signals relevant to procurement decisions
GLP-1R expression in rodent and human tissue maps to pancreatic islets, hypothalamic satiety centres, vagal afferents, and cardiac tissue, which is why metabolic and cardiovascular endpoints both feature in semaglutide research designs. Earlier non-clinical pharmacology established dose-dependent reductions in body weight and improvements in glucose tolerance in diet-induced obese rodents. That foundational dose-response work largely predates 2020 and should be treated as background rather than current primary literature. Teams designing new protocols should pull the latest PubMed-indexed dose-response data directly rather than rely on a single legacy citation.
Separating clinical context from research-chemical use
Clinical programmes such as SUSTAIN and PIONEER generated the cardiovascular and glycaemic outcome data that underpin Ozempic's registration as a Schedule-level medicine in South Africa. Those trials used registered, GMP-manufactured semaglutide administered to human participants under ethics approval. Their endpoints do not transfer to unregistered research-grade pens. The HD Semaglutide 10 Pen is supplied strictly for in vitro and non-clinical investigation. Any extrapolation to human therapeutic effect sits outside its intended scope.
Researchers building combination GLP-1 protocols frequently benchmark semaglutide against shorter-pen alternatives such as the Body Pharm Semaglutide 6 Pen or against dual GIP/GLP-1 candidates like Tirsema when modelling additive receptor engagement.
HD Labs 10 Pen vs Body Pharm Semaglutide 6 Pen
Choose the HD Labs 10 Pen for extended dose-ranging studies or multi-cohort work where a single sealed device must cover more actuations. Choose the Body Pharm Semaglutide 6 Pen for shorter pilot protocols or single-cohort feasibility runs where the smaller dose count reduces wastage if a study is terminated early.
Live ZAR pricing for both pens was not publicly indexed at the time of writing. Confirm prices with the supplier before procurement sign-off. The table below uses the structure procurement teams should populate from a current quote rather than fixed figures.
| Specification | HD Semaglutide 10 Pen | Body Pharm Semaglutide 6 Pen |
|---|---|---|
| Total doses per pen | 10 | 6 |
| Total peptide content (mg) | Contact supplier | Contact supplier |
| Concentration (mg/mL) | Contact supplier | Contact supplier |
| Unit price (R) | Contact for pricing | Contact for pricing |
| Cost per dose (R) | Calculate from quote | Calculate from quote |
| Cost per mg peptide (R) | Calculate from quote | Calculate from quote |
Matching pen format to protocol design
A 10-dose pen typically reduces per-dose handling variance across a longer time-course because the same sealed cartridge serves successive actuations. This matters when an in vitro dosing schedule runs 8–10 weeks. The 6-dose format suits short pilots, dose-finding pre-studies, or split-cohort designs where two pens give better redundancy than one larger device.
Researchers screening dual-agonist hypotheses alongside pure GLP-1 work often hold a Tirsema reference in parallel to benchmark receptor coverage. It is worth costing this into the same purchase order to consolidate freight and documentation.
How Semaglutide Fits Into a GLP-1 Research Stack
Semaglutide is a GLP-1 receptor mono-agonist, which makes it the cleanest reference compound for isolating GLP-1R-mediated effects from broader incretin or glucagon signalling in a multi-compound research stack. Tirzepatide adds GIP receptor agonism (GLP-1R + GIPR dual), and retatrutide extends activity to the glucagon receptor as well (GLP-1R + GIPR + GCGR triple). Receptor coverage broadens at each step away from semaglutide [4, 2025 update].
For pharmacology teams running receptor-selectivity comparisons, semaglutide is the GLP-1R "anchor" against which dual- and triple-agonist effects are subtracted. If a model shows weight or glucose tolerance shifts under tirzepatide that exceed the semaglutide arm at matched GLP-1R occupancy, the delta is generally attributed to GIPR engagement (and, with retatrutide, GCGR as well). Running semaglutide in parallel rather than relying on historical controls reduces between-batch and between-cohort variance.
Complementary compounds on the same catalogue
Researchers structuring a full incretin stack typically pair the HD Semaglutide 10 Pen with the Body Pharm Semaglutide 6 Pen for split-cohort redundancy, and add a Tirsema arm where a dual-agonist comparator is required within a single protocol.
Any protocol combining two or more GLP-1 agonists, or layering an agonist with a separate metabolic peptide, requires independent ethical clearance and pharmacovigilance review at the institutional level before procurement is finalised. SAHPRA continues to treat semaglutide as a scheduled medicinal active ingredient irrespective of "research" labelling. Combination work must sit within an authorised in vitro or non-clinical framework.
Ordering, Shipping, and Storage in South Africa
Orders placed through the jcsg.org/za product page move through a standard cart and secure checkout. Dispatch typically occurs on the next working day after payment clearance. Tracked courier delivery reaches most South African metros within 2–4 working days (outlying areas 3–6 working days). Packaging is plain and discreet, with the tracking number issued by email on dispatch.
Receipt and cold-chain handling
On receipt, I move the pen straight to refrigerated storage at 2–8 °C, protected from light and kept upright in its original carton. Do not freeze: ice crystal formation disrupts peptide conformation and can compromise dose accuracy at the actuator. Unopened pens held continuously within the 2–8 °C range remain suitable for research use until the printed expiry. HD Labs has not published a public post-first-actuation in-use period. Internal stability data or a conservative in-house limit should govern that window.
Regulatory responsibility sits with the buyer
The product ships as a research chemical for in vitro, non-clinical use only. SAHPRA's November 2024 position statement is unambiguous that semaglutide remains a scheduled medicinal active ingredient when intended for human administration, irrespective of "research" labelling. Unregistered semaglutide preparations sold online fall under enforcement scrutiny. Procurement officers should confirm that the intended protocol sits within an authorised in vitro or non-clinical framework, with institutional ethics and pharmacovigilance sign-off on file before ordering. Researchers building a comparator arm can stage parallel procurement of the Body Pharm Semaglutide 6 Pen or a dual-agonist reference such as Tirsema under the same compliance envelope.
Research Use Disclaimer and Regulatory Notice
The HD Semaglutide 10 Pen is supplied strictly for in vitro and laboratory research use. It is not a pharmaceutical product, is not intended for human or veterinary administration, and no therapeutic, diagnostic or prophylactic claims are made or implied. It is sold as a research chemical only. Any extrapolation to clinical use falls outside the scope of this listing.
Responsibility for lawful and ethical use rests with the purchasing researcher and their institution. SAHPRA's 8 November 2024 position statement confirms that semaglutide remains a scheduled medicinal active ingredient under the Medicines and Related Substances Act 101 of 1965 whenever it is intended for human administration, regardless of "research" labelling. Unregistered preparations sold online are treated as unauthorised medicines. Protocols involving live animals additionally require approval from an accredited institutional animal ethics committee under the Animals Protection Act 71 of 1962, with NSPCA oversight where applicable.
Before placing an order, confirm that your project sits within a documented in vitro or non-clinical framework with ethics sign-off on file. Procurement teams comparing formats can review the Body Pharm Semaglutide 6 Pen or the dual-agonist reference Tirsema under the same compliance envelope.
Frequently Asked Questions
How does the 10 Pen format differ from a lyophilised vial?
A pen delivers pre-measured actuations from a sealed cartridge, which reduces pipetting variance across repeated-dose bench protocols compared with reconstituting a lyophilised vial each session. The same mechanical actuator produces consistent volume with each click. Vials remain preferable where researchers need full control over reconstitution volume and solvent choice. Exact mg/mL concentration and µL per click for the HD Labs pen should be confirmed against the batch CoA supplied with the order, as these values are not published on an open product sheet.
How should the pen be stored after first actuation?
Store unopened pens at 2–8 °C, protected from light, consistent with general GLP-1 analogue handling. HD Labs does not publish a post-first-use stability window for this pen. Confirm the in-use duration directly with the supplier or batch documentation before designing time-course experiments.
Is it legal to buy semaglutide research peptide in South Africa?
Semaglutide remains a scheduled medicinal active under the Medicines and Related Substances Act 101 of 1965. SAHPRA's 8 November 2024 position statement treats unregistered preparations sold online as unauthorised medicines when intended for human use. Purchase for genuine in vitro research sits with the institution's compliance officer, who must document non-clinical intent and any required ethics approvals.
What purity specification does HD Labs publish?
HD Labs has not posted a publicly indexed 2025–2026 CoA specifying purity percentage or analytical method for this pen. Request the batch-specific certificate at order confirmation and verify HPLC purity and identity confirmation before release into a protocol.
Can semaglutide and tirzepatide be combined in one protocol?
Dual GLP-1 and GIP/GLP-1 agonist work is an active research area. Combination formats such as Tirsema are used to study additive receptor pharmacology in vitro, allowing researchers to measure the independent contribution of each receptor pathway. Live-animal combination studies require accredited ethics committee approval under the Animals Protection Act 71 of 1962. Researchers comparing single-agonist formats can review the Body Pharm Semaglutide 6 Pen for an alternative actuation count.
Next Steps
Contact your institutional compliance officer to confirm that your protocol sits within an authorised in vitro or non-clinical framework. Request the batch certificate of analysis directly from HD Labs to verify concentration and volume-per-actuation figures. If you are designing a multi-agonist study, obtain quotes for the Body Pharm Semaglutide 6 Pen and Tirsema in the same purchase order to consolidate shipping and documentation.
